XML 121 R37.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Revenues (Tables)
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Revenue by product
Revenues by product are summarized as follows:
 
For the Years Ended December 31,
 
2019
 
2018
 
2017
(In millions)
United
States
 
Rest of
World
 
Total
 
United
States
 
Rest of
World
 
Total
 
United
States
 
Rest of
World
 
Total
Multiple Sclerosis (MS):
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TECFIDERA
$
3,306.5

 
$
1,126.2

 
$
4,432.7

 
$
3,253.2

 
$
1,020.9

 
$
4,274.1

 
$
3,294.0

 
$
920.0

 
$
4,214.0

Interferon*
1,426.6

 
675.2

 
2,101.8

 
1,668.3

 
694.7

 
2,363.0

 
1,889.1

 
756.7

 
2,645.8

TYSABRI
1,041.8

 
850.4

 
1,892.2

 
1,025.0

 
839.0

 
1,864.0

 
1,113.8

 
859.3

 
1,973.1

VUMERITY
5.5

 
—

 
5.5

 
—

 
—

 
—

 
—

 
—

 
—

FAMPYRA
—

 
97.1

 
97.1

 
—

 
92.7

 
92.7

 
—

 
91.6

 
91.6

ZINBRYTA
—

 
—

 
—

 
—

 
1.4

 
1.4

 
—

 
52.7

 
52.7

Subtotal: MS Product Revenues
5,780.4

 
2,748.9

 
8,529.3

 
5,946.5

 
2,648.7

 
8,595.2

 
6,296.9

 
2,680.3

 
8,977.2

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spinal Muscular Atrophy:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SPINRAZA
933.4

 
1,163.6

 
2,097.0

 
854.0

 
870.2

 
1,724.2

 
657.0

 
226.7

 
883.7

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biosimilars:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
BENEPALI
—

 
486.2

 
486.2

 
—

 
485.2

 
485.2

 
—

 
370.8

 
370.8

IMRALDI
—

 
184.0

 
184.0

 
—

 
16.7

 
16.7

 
—

 
—

 
—

FLIXABI
—

 
68.1

 
68.1

 
—

 
43.2

 
43.2

 
—

 
9.0

 
9.0

Subtotal: Biosimilar product revenues
—

 
738.3

 
738.3

 
—

 
545.1

 
545.1

 
—

 
379.8

 
379.8

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Other:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FUMADERM
—

 
15.2

 
15.2

 
—

 
22.3

 
22.3

 
—

 
39.6

 
39.6

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hemophilia:
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ELOCTATE
—

 
—

 
—

 
—

 
—

 
—

 
42.2

 
6.2

 
48.4

ALPROLIX
—

 
—

 
—

 
—

 
—

 
—

 
21.0

 
5.0

 
26.0

Subtotal: Hemophilia product revenues
—

 
—

 
—

 
—

 
—

 
—

 
63.2

 
11.2

 
74.4

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total product revenues
$
6,713.8

 
$
4,666.0

 
$
11,379.8

 
$
6,800.5

 
$
4,086.3

 
$
10,886.8

 
$
7,017.1

 
$
3,337.6

 
$
10,354.7

*Interferon includes AVONEX and PLEGRIDY.
Analysis of change in reserves
An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
2019
 
 
 
 
 
 
 
Beginning balance
$
127.8

 
$
888.8

 
$
34.7

 
$
1,051.3

Current provisions relating to sales in current year
666.2

 
3,011.5

 
20.9

 
3,698.6

Adjustments relating to prior years
0.3

 
(54.1
)
 
5.5

 
(48.3
)
Payments/returns relating to sales in current year
(535.5
)
 
(2,242.9
)
 
(0.2
)
 
(2,778.6
)
Payments/returns relating to sales in prior years
(127.7
)
 
(576.0
)
 
(20.4
)
 
(724.1
)
Ending balance
$
131.1

 
$
1,027.3

 
$
40.5

 
$
1,198.9


(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
2018
 
 
 
 
 
 
 
Beginning balance
$
109.6

 
$
606.0

 
$
46.0

 
$
761.6

Current provisions relating to sales in current year
679.3

 
2,686.7

 
23.1

 
3,389.1

Adjustments relating to prior years
(0.3
)
 
(10.0
)
 
(1.8
)
 
(12.1
)
Payments/returns relating to sales in current year
(551.7
)
 
(1,887.6
)
 
(1.1
)
 
(2,440.4
)
Payments/returns relating to sales in prior years
(109.1
)
 
(506.3
)
 
(31.5
)
 
(646.9
)
Ending balance
$
127.8

 
$
888.8

 
$
34.7

 
$
1,051.3

(In millions)
Discounts
 
Contractual
Adjustments
 
Returns
 
Total
2017
 
 
 
 
 
 
 
Beginning balance
$
71.6

 
$
482.7

 
$
51.2

 
$
605.5

Current provisions relating to sales in current year
583.0

 
2,307.4

 
26.9

 
2,917.3

Adjustments relating to prior years
(0.1
)
 
15.0

 
(8.9
)
 
6.0

Payments/returns relating to sales in current year
(475.8
)
 
(1,756.9
)
 
(0.1
)
 
(2,232.8
)
Payments/returns relating to sales in prior years
(69.1
)
 
(442.2
)
 
(23.1
)
 
(534.4
)
Ending balance
$
109.6

 
$
606.0

 
$
46.0

 
$
761.6
Total reserves included in consolidated balance sheet
The total reserves above, which are included in our consolidated balance sheets, are summarized as follows:
 
As of December 31,
(In millions)
2019
 
2018
Reduction of accounts receivable
$
197.8

 
$
176.6

Component of accrued expenses and other
1,001.1

 
874.7

Total revenue-related reserves
$
1,198.9

 
$
1,051.3
Revenues from anti-CD20 therapeutic programs
Revenues from anti-CD20 therapeutic programs are summarized in the table below. For purposes of this footnote we refer to RITUXAN and RITUXAN HYCELA collectively as RITUXAN.
 
For the Years Ended December 31,
(In millions)
2019
 
2018
 
2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses
$
1,542.4

 
$
1,431.9

 
$
1,316.4

Other revenues from anti-CD20 therapeutic programs
748.0

 
548.3

 
242.8

Total revenues from anti-CD20 therapeutic programs
$
2,290.4

 
$
1,980.2

 
$
1,559.2


Revenues from anti-CD20 therapeutic programs are summarized as follows:
 
For the Years Ended December 31,
(In millions)
2019
 
2018
 
2017
Biogen's share of pre-tax profits in the U.S. for RITUXAN and GAZYVA, including the reimbursement of selling and development expenses
$
1,542.4

 
$
1,431.9

 
$
1,316.4

Other revenues from anti-CD20 therapeutic programs
748.0

 
548.3

 
242.8

Total revenues from anti-CD20 therapeutic programs
$
2,290.4

 
$
1,980.2

 
$
1,559.2
Other revenues
Other revenues are summarized as follows:
 
For the Years Ended December 31,
(In millions)
2019
 
2018
 
2017
Revenues from collaborative and other relationships:
 
 
 
 
 
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie Inc.
$
—

 
$
(8.6
)
 
$
(16.9
)
Revenues earned under our technical development services and manufacturing service agreements and royalty revenues on biosimilar products with Samsung Bioepis
106.2

 
96.4

 
42.7

Revenues earned under manufacturing services agreement on shipments of ELOCTA and ALPROLIX to Swedish Orphan Biovitrum AB (Sobi) and royalties from Sobi on sales of ELOCTA and ALPROLIX
—

 
—

 
10.7

Other royalty and corporate revenues:
 
 
 
 
 
Royalty
17.0

 
38.7

 
69.8

Other corporate
584.5

 
459.4

 
253.7

Total other revenues
$
707.7

 
$
585.9

 
$
360.0